Biomarker Solutions



Structural Magnetic Resonance Imaging

In CNS drug research, structural MRI can be useful to define sub-groups of patients (e.g. dementia, MCI) or to monitor long-term (> six months) drug effects.

Special offer: Quantifying volumes of cholinergic nuclei in the brain

MRI-Darstellung des Hirns
(A) The cholinergic NBM ( Ncl. Basalis Magnocellularis, formerly Meynert) viewed from anterior at the level of the anterior commissure. (B) displays the NBM at whole extent. The anterior-intermediate sector is coloured in blue, the posterior sector in yellow. DARTEL-based procedure implemented in SPM8 and a validated probabilistic map of the basal forebrain.
Lammers F, Mobascher A, Musso F, Shah NJ, Warbrick T, Zaborszky L, Winterer G (2016). Effects of Ncl. Basalis Meynert volume on the Trail-Making-Test are restricted to the left hemisphere. BRAIN AND BEHAVIOR. 6(1): DOI: 10.1002/brb3.421

We offer:

  • Study set-up and MRI data acquisition incl. QC/monitoring (and SOP for multicenter data acquisition)
  • T2-weighted incl. high-resolution (e.g. hippocampus volume), T1-weighted, diffusion tensor imaging (DTI)
  • Data analysis: VBM, ROI analyses including cholinergic nuclei (DARTEL Toolbox), fractional anisotropy, diffusivity, tractography, surface rendering using the Freesurfer software package or in-house software
  • Reference data from N = 100 clinically stable schizophrenia patients and > N = 100 subjects with MCI (Mild Cognitive Impairment) are available (in addition to N = 1000 healthy control subjects)
  • Upon request: Access to 7T ultrahigh-field MRI (e.g. for MR-imaging of blood-brain barrier, currently under development)

© PI-PharmaImage Germany GmbH 2017 | Webdesign: blickpunkt x, Köln